Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 298, Issue 3, 2010, Pages

  Bongartz, L G ^a   Braam, B ^b   Verhaar, M C ^a   Cramer, M J ^a   Goldschmeding, R ^a   Gaillard, C A ^c   Doevendans, P A ^a   Joles, J A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Cardiorenal; Echocardiography; Glomerulosclerosis; Proteinuria

Indexed keywords

N(G) NITROARGININE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; GLOMERULOSCLEROSIS; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; ECHOCARDIOGRAPHY; ENZYME INHIBITORS; HEMATOCRIT; HYPERTENSION, RENAL; MALE; NEPHRECTOMY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; POULT ENTERITIS MORTALITY SYNDROME; PROTEINURIA; RATS; RATS, INBRED LEW; RENAL INSUFFICIENCY, CHRONIC; SYSTOLE; URINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77749328927     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00727.2009     Document Type: Article

References (47)

1. Attia DM, Ni ZN, Boer P, Attia MA, Goldschmeding R, Koomans HA, Vaziri ND, Joles JA. Proteinuria is preceded by decreased nitric oxide synthesis and prevented by a NO donor in cholesterol-fed rats. Kidney Int 61: 1776-1787, 2002.
2. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294: F1-F9, 2008.
3. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992.
4. Baylis C, Vallance P. Measurement of nitrite and nitrate levels in plasma and urine-what does this measure tell us about the activity of the endogenous nitric oxide system? Curr Opin Nephrol Hypertens 7: 59-62, 1998.
5. Blot S, Arnal JF, Xu Y, Gray F, Michel JB. Spinal cord infarcts during long-term inhibition of nitric oxide synthase in rats. Stroke 25: 1666-1673, 1994.
6. Blum M, Yachnin T, Wollman Y, Chernihovsky T, Peer G, Grosskopf I, Kaplan E, Silverberg D, Cabili S, Iaina A. Low nitric oxide production in patients with chronic renal failure. Nephron 79: 265-268, 1998.
7. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 26: 11-17, 2005.
8. de Mattos AM, Siedlecki A, Gaston RS, Perry GJ, Julian BA, Kew CE 2nd, Deierhoi MH, Young C, Curtis JJ, Iskandrian AE. Systolic dysfunction portends increased mortality among those waiting for renal transplant. J Am Soc Nephrol 19: 1191-1196, 2008.
9. Erdely A, Freshour G, Baylis C. Resistance to renal damage by chronic nitric oxide synthase inhibition in the Wistar-Furth rat. Am J Physiol Regul Integr Comp Physiol 290: R66-R72, 2006.
10. Erdely A, Wagner L, Muller V, Szabo A, Baylis C. Protection of Wistar Furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase. J Am Soc Nephrol 14: 2526-2533, 2003.
11. Fujihara CK, De Nucci G, Zatz R. Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol 5: 1498-1507, 1995.
12. Fujihara CK, Sena CR, Malheiros DM, Mattar AL, Zatz R. Short-term nitric oxide inhibition induces progressive nephropathy after regression of initial renal injury. Am J Physiol Renal Physiol 290: F632-F640, 2006.
13. G-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br J Pharmacol 101: 625-631, 1990.
14. Gardiner SM, Kemp PA, Bennett T, Palmer RM, Moncada S. Nitric oxide synthase inhibitors cause sustained, but reversible, hypertension and hindquarters vasoconstriction in Brattleboro rats. Eur J Pharmacol 213: 449-451, 1992.
15. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
16. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47: 884-890, 1995.
17. Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 9: 195-201, 2004.
18. Huang M, Manning RD Jr, LeBlanc MH, and Hester RL. Overall hemodynamic studies after the chronic inhibition of endothelial-derived nitric oxide in rats. Am J Hypertens 8: 358-364, 1995.
19. Jie KE, Verhaar MC, Cramer MJ, van der Putten K, Gaillard CA, Doevendans PA, Koomans HA, Joles JA, Braam B. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 291: F932-F944, 2006.
20. Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, Floege J. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 11: 669-683, 2000.
21. Joles JA, van Goor H, Koomans HA. Estrogen induces glomerulosclerosis in analbuminemic rats. Kidney Int 53: 862-868, 1998.
22. Kamijo H, Higuchi M, Hora K. Chronic inhibition of nitric oxide production aggravates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Nephron Physiol 104: 12-22, 2006.
23. Kang DH, Nakagawa T, Feng L, Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161: 239-248, 2002.
24. Kennedy D, Omran E, Periyasamy SM, Nadoor J, Priyadarshi A, Willey JC, Malhotra D, Xie Z, Shapiro JI. Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J Am Soc Nephrol 14: 90-97, 2003.
25. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 47: 488-495, 2006.
26. Klabunde RE, Ritger RC, Helgren MC. Cardiovascular actions of inhibitors of endothelium-derived relaxing factor (nitric oxide) formation/release in anesthetized dogs. Eur J Pharmacol 199: 51-59, 1991.
27. Koeners MP, Braam B, van der Giezen DM, Goldschmeding R, Joles JA. A perinatal nitric oxide donor increases renal vascular resistance and ameliorates hypertension and glomerular injury in adult fawn-hooded hypertensive rats. Am J Physiol Regul Integr Comp Physiol 294: R1847-R1855, 2008.
28. Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E. Myocardial interstitial fibrosis in experimental uremia-implications for cardiac compliance. Kidney Int 33: 804-811, 1988.
29. Michea L, Villagran A, Urzua A, Kuntsmann S, Venegas P, Carrasco L, Gonzalez M, Marusic ET. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 52: 295-300, 2008.
30. Moreno H, Jr, Metze K, Bento AC, Antunes E, Zatz R, de Nucci G. Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol 91: 248-255, 1996.
31. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11: 1277-1285, 1996.
32. Rambausek M, Ritz E, Mall G, Mehls O, Katus H. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 28: 775-782, 1985.
33. Rasband WS. ImageJ [online at http://rsb.info.nih.gov/ij/]. Bethesda, MD: National Institutes of Health, 1997-2008.
34. Reddy V, Bhandari S, Seymour AM. Myocardial function, energy provision, and carnitine deficiency in experimental uremia. J Am Soc Nephrol 18: 84-92, 2007.
35. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 52: 1527-1539, 2008.
36. Seddon M, Shah AM, Casadei B. Cardiomyocytes as effectors of nitric oxide signalling. Cardiovasc Res 75: 315-326, 2007.
37. Shultz PJ, Tolins JP. Adaptation to increased dietary salt intake in the rat. Role of endogenous nitric oxide. J Clin Invest 91: 642-650, 1993.
38. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 75: 800-808, 2009.
39. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 89: 2035-2040, 1994.
40. Szabo AJ, Muller V, Chen GF, Samsell LJ, Erdely A, Baylis C. Nephron number determines susceptibility to renal mass reduction-induced CKD in Lewis and Fisher 344 rats: implications for development of experimentally induced chronic allograft nephropathy. Nephrol Dial Transplant 23: 2492-2495, 2008.
41. ω-nitro-L-arginine in rats. Br J Pharmacol 111: 394-396, 1994.
42. Vercauteren SR, Ysebaert DK, De Greef KE, Eyskens EJ, De Broe ME. Chronic reduction in renal mass in the rat attenuates ischemia/reperfusion injury and does not impair tubular regeneration. J Am Soc Nephrol 10: 2551-2561, 1999.
43. Verhagen AM, Koomans HA, Joles JA. Predisposition of spontaneously hypertensive rats to develop renal injury during nitric oxide synthase inhibition. Eur J Pharmacol 411: 175-180, 2001.
44. Wever R, Boer P, Hijmering M, Stroes E, Verhaar M, Kastelein J, Versluis K, Lagerwerf F, van Rijn H, Koomans H, Rabelink T. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 19: 1168-1172, 1999.
45. Wyatt HL, Meerbaum S, Heng MK, Gueret P, Corday E. Cross-sectional echocardiography. III. Analysis of mathematic models for quantifying volume of symmetric and asymmetric left ventricles. Am Heart J 100: 821-828, 1980.
46. Yamada SS, Sassaki AL, Fujihara CK, Malheiros DM, De Nucci G, Zatz R. Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Hypertension 27: 1165-1172, 1996.
47. Zolty R, Hynes PJ, Vittorio TJ. Severe left ventricular systolic dysfunction may reverse with renal transplantation: uremic cardiomyopathy and cardiorenal syndrome. Am J Transplant 8: 2219-2224, 2008.